
EHA 2021 VIRTUAL SCIENTIFIC PROGRAM
JUNE 9–17, 2021

Bristol Myers Squibb

Compendium of presentations

Click on a therapeutic area to see a list of scheduled presentations

Table of Contents

Lymphoma

Multiple Myeloma

Myeloid

Lymphoma

NON-HODGKIN LYMPHOMA

Poster Presentations

Presentation #EP539: Clinical Outcomes in Patients With Relapsed/Refractory Large B-Cell Lymphoma Receiving Third-Line Therapy: A Multicenter, Retrospective, Real-world Study in the United Kingdom

Lead Author and Presenter: Christopher Fox, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

Session: Aggressive Non-Hodgkin lymphoma - Clinical

Presentation #EP541: OUTREACH: Preliminary Safety & Efficacy Results From a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) in the Non-university Setting

Lead Author and Presenter: John Godwin, Providence Cancer Center, Earle A. Chiles Research Institute, Portland, OR, United States

Session: Aggressive Non-Hodgkin lymphoma - Clinical

Presentation #EP1165: Systematic Literature Review (SLR) of the Efficacy and Safety of Second-Line (2L) Treatments for Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lead Author and Presenter: Fei Fei Liu, Bristol Myers Squibb, Princeton, NJ, United States

Session: Quality of Life, Palliative Care, Ethics and Health Economics

Presentation #EP1169: Use of Chimeric Antigen Receptor T cell Therapies in Patients With Large B-Cell Lymphoma in the Real-World Setting: Systematic Literature Review

Lead Author and Presenter: Fei Fei Liu, Bristol Myers Squibb, Princeton, NJ, United States

Session: Quality of Life, Palliative Care, Ethics and Health Economics

HODGKIN LYMPHOMA

Poster Presentation

Presentation #EP1178: Targeted Landscape Review for Understanding Lymphoma Patient-Reported Outcome Assessment in the Era of Emerging Therapies

Lead Author and Presenter: Stacie Hudgens, Regulatory and Access, Clinical Outcomes Solutions, Tucson, AZ, United States

Session: Quality of Life, Palliative Care, Ethics and Health Economics

Multiple Myeloma

MULTIPLE MYELOMA

Oral Presentation

Presentation #S187: Iberdomide (IBER) in Combination With Dexamethasone (DEX) and Daratumumab (DARA), Bortezomib (BORT), or Carfilzomib (CFX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

Lead Author and Presenter: Sagar Lonial, Winship Cancer Institute, Emory University, Atlanta, GA, United States

Session: New Diagnostic and Therapeutic Approaches in Multiple Myeloma and AL Amyloidosis

EHA Thematic Day Q&A: June 14, 2021 4:00 PM-4:45 PM (CEST) Virtual Room 3

Poster Presentations

Presentation #EP747: Anakinra Prophylaxis in Patients With Relapsed/Refractory Multiple Myeloma Receiving Orvacabtagene Autoleucl (orva-cel)

Lead Author and Presenter: Luciano Costa, University of Alabama Birmingham, Birmingham, AL, United States

Session: Gene Therapy, Cellular Immunotherapy and Vaccination - Clinical

Presentation #EP984: Characteristics of Neurotoxicity Associated With Idecabtagene Vicleucl (Ide-cel, bb2121) in Patients With Relapsed and Refractory Multiple Myeloma in the Pivotal Phase 2 KarMMa Study

Lead Author and Presenter: Salomon Manier, Department of Hematologic Malignancies, Lille University Hospital, Lille, France

Session: Myeloma and Other Monoclonal Gammopathies - Clinical

Presentation #EP988: Pomalidomide, Bortezomib, and Dexamethasone After 1 Prior Line of Therapy in Relapsed or Refractory Multiple Myeloma: A Safety Subanalysis of the Phase 3 OPTIMISMM Trial

Lead Author and Presenter: Katja Weisel, Department of Oncology, Hematology, and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Session: Myeloma and Other Monoclonal Gammopathies - Clinical

Presentation #EP1009: Idecabtagene Vicleucel (Ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in Patients With Relapsed and Refractory Multiple Myeloma: Updated KarMMa Results

Lead Author and Presenter: Albert Oriol, Institut Josep Carreras and Institut Catala d'Oncologia, Hospital Germans Trias I Pujol, Badalona, Spain

Session: Myeloma and Other Monoclonal Gammopathies - Clinical

Presentation #EP1013: A Meta-analysis of Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed or Refractory Multiple Myeloma After Lenalidomide Exposure

Lead Author and Presenter: Faith E. Davies, NYU Grossman School of Medicine, Clinical Myeloma Program, Perlmutter Cancer Center, New York, NY, United States

Session: Myeloma and Other Monoclonal Gammopathies - Clinical

Presentation #EP1019: Pomalidomide, Dexamethasone, and Daratumumab in Relapsed Refractory Multiple Myeloma (MM-014 Phase 2 Trial): A Subanalysis of Patients Previously Treated With Lenalidomide and a Proteasome Inhibitor

Lead Author and Presenter: Nizar J. Bahlis, Tom Baker Cancer Centre, Calgary, Canada

Session: Myeloma and Other Monoclonal Gammopathies - Clinical

Publication Only

Publication #PB1673: Real-World Treatment Patterns in Clinical Outcomes in Patients With Multiple Myeloma in Different Geographical Regions: Findings From a Systematic Literature Review

Lead Author: Elena Zamangi, University of Bologna, Bologna, Italy

Myeloid

β -THALASSEMIA

Oral Presentation

Presentation #S101: The BEYOND Study: Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Luspatercept in Adult Patients With Non-transfusion Dependent Beta-Thalassemia

Lead Author and Presenter: Ali T. Taher, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

Session: Presidential Symposium; June 11, 2021 4:15 PM-4:30 PM (CEST) Virtual Room 1

Poster Presentations

Presentation #EP1304: Fewer Red Blood Cell Transfusion Units and Visits Across Baseline Transfusion Burden Levels in Patients With Beta-Thalassemia Treated With Luspatercept in the Phase 3 BELIEVE Trial

Lead Author and Presenter: Ali T. Taher, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

Session: Thalassemias

Presentation #EP1305: Long-Term Efficacy and Safety Outcomes in the Phase 2 Study of Luspatercept in β -thalassemia

Lead Author and Presenter: Antonio Piga, University of Turin, Turin, Italy

Session: Thalassemias

Presentation #EP1306: Benefit of Continuing Therapy With Luspatercept in Patients With Beta-Thalassemia Who Do Not Achieve $\geq 33\%$ Reduction in Red Blood Cell (RBC) Transfusion Burden (TB) in Weeks 13-24 in the BELIEVE Trial

Lead Author and Presenter: Antonio Piga, University of Turin, Turin, Italy

Session: Thalassemias

Presentation #EP1315: Quantifying the Healthcare Resource Use and Clinical Outcomes of Patients With Beta Thalassemia in England

Lead Author and Presenter: James Farrell, Bristol Myers Squibb, Princeton, NJ, United States

Session: Thalassemias

MYELOYDYSPLASTIC SYNDROME

Poster Presentations

Presentation #EP915: Benefit of Continuing Luspatercept Therapy in Patients With Lower-Risk Myelodysplastic Syndromes Who Did Not Achieve Red Blood Cell Transfusion Independence by Week 25 in the MEDALIST Study

Lead Author and Presenter: Ulrich Germing, University Hospital of Düsseldorf, Düsseldorf, Germany

Session: Myelodysplastic Syndromes - Clinical

Presentation #EP920: Luspatercept Reduces Red Blood Cell Transfusions in Patients With Lower-Risk Myelodysplastic Syndromes Regardless of Baseline Transfusion Burden in the MEDALIST Study

Lead Author and Presenter: Guillermo Garcia-Manero, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session: Myelodysplastic Syndromes - Clinical

Presentation #EP930: Quantifying the Healthcare Resource Use and Clinical Outcomes of Patients With Myelodysplastic Syndrome With Ringed Sideroblasts in England

Lead Author and Presenter: James Farrell, Bristol Myers Squibb, Princeton, NJ, United States

Session: Myelodysplastic Syndromes - Clinical

Presentation #EP1182: Health-Related Quality of Life (HRQoL) in Patients (Pts) With Myelodysplastic Syndromes (MDS) in the CONNECT® Myeloid Disease Registry

Lead Author: Dennis A. Revicki, Outcomes Research Consulting, Sarasota, FL, United States

Session: Quality of Life, Palliative Care, Ethics and Health Economics

Publication Only

Publication #PB1619: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to Lower-Risk MDS in ESA-Naive Patients Requiring RBC Transfusions (the COMMANDS trial)

Lead Author: Matteo Della Porta, Cancer Center IRCCS Humanitas Research Hospital and Department of Biomedical Sciences, Humanitas University, Milan, Italy

ACUTE MYELOID LEUKEMIA

Oral Presentations

Presentation #S131: Survival Outcomes From the QUAZAR AML-001 Trial With Oral Azacitidine for Patients With Acute Myeloid Leukemia in Remission by Disease Subtype, Cytogenetic Risk, and NPM1 Mutation Status at Diagnosis

Lead Author and Presenter: Hartmut Döhner, Universitätsklinikum Ulm, Ulm, Germany

Session: AML Classification

EHA Thematic Day Q&A: June 17, 2021 7:45 PM-8:30 PM (CEST) Virtual Room 2

Presentation #S311: Estimated Hospitalization-Related Costs With Oral Azacitidine (Oral-AZA) vs Placebo (PBO) for Remission Maintenance in Patients With Acute Myeloid Leukemia (AML) in Spain and the United Kingdom (UK)

Lead Author: Christopher Pocock, Kemp and Canterbury Hospital, Canterbury, United Kingdom

Presenter: Esther Natalie Oliva, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy

Session: Patient's Voice and Health Outcomes in Hematology

EHA Thematic Day Q&A: June 15, 2021 8:45 PM-9:30 PM (CEST) Virtual Room 1

Poster Presentations

Presentation #EP428: Prognostic Factors of Overall and Relapse-Free Survival for Patients With Acute Myeloid Leukemia (AML) in Remission: Multivariate Analyses From the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA)

Lead Author and Presenter: Gail Roboz, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, United States

Session: Acute Myeloid Leukemia - Clinical

Presentation #EP445: Hematologic Adverse Events and Management Strategies for Patients With Acute Myeloid Leukemia (AML) in First Remission Receiving Oral Azacitidine (Oral-AZA) in the Phase 3 QUAZAR AML-001 Trial

Lead Author and Presenter: Farhad Ravandi, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session: Acute Myeloid Leukemia - Clinical

Presentation #EP446: Comparative Efficacy of Oral Versus Injectable Azacitidine in Patients With AML in First Remission After Intensive Chemotherapy: An Indirect Treatment Comparison (Sub-Analysis Update)

Lead Author and Presenter: Clara Chen, Bristol Myers Squibb, Princeton, NJ, United States

Session: Acute Myeloid Leukemia - Clinical

Presentation #EP457: A Phase 3 Study of Enasidenib (ENA) Versus Conventional Care Regimens (CCR) in Older Patients With Late-Stage Mutant-IDH2 (MIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Lead Author and Presenter: Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session: Acute Myeloid Leukemia - Clinical

Presentation #EP465: Updated Pharmacodynamic and Survival Outcomes From the AG221-AML-005 Trial of Enasidenib (ENA) Plus Azacitidine (AZA) in Patients With Mutant IDH2 Newly Diagnosed Acute Myeloid Leukemia (ND-AML)

Lead Author and Presenter: Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session: Acute Myeloid Leukemia - Clinical

Publication Only

Publication #PB1395: Systematic Literature Review of the Efficacy and Safety of Maintenance Therapies for Adults With Acute Myeloid Leukemia in Complete Remission Who Are Ineligible for Hematopoietic Stem Cell Transplant

Lead Author: Beatrice Suero, Eversana, Burlington, ON, Canada

Publication #PB1398: Patient Preferences for Maintenance Therapy of Acute Myeloid Leukemia: A Discrete Choice Experiment Subanalysis of Patients in Germany and Italy

Lead Author: Katelyn Cutts, Evidera, Bethesda, MD, United States

Publication #PB1406: European Guidelines and Real-World Evidence of Maintenance Treatments for Adults With Acute Myeloid Leukemia in First Complete Remission

Lead Author: Moez Ahmed, Eversana, Burlington, ON, Canada

MYELOFIBROSIS

Oral Presentation

Presentation #S203: Overall and Progression-Free Survival in Patients Treated With Fedratinib as First-Line Myelofibrosis (MF) Therapy and After Prior Ruxolitinib (RUX): Results From the JAKARTA and JAKARTA2 Trials

Lead Author and Presenter: Claire Harrison, Guy's and St. Thomas' Hospital, London, United Kingdom

Session: Therapies and Targets in MPN

EHA Thematic Day Q&A: June 16, 2021 4:00 PM-4:45 PM (CEST) Virtual Room 2

Poster Presentation

Presentation #EP1062: Fedratinib Demonstrates Limited Suppression of T- and Natural Killer- (NK) Cell Activity Ex Vivo Compared With Ruxolitinib at Clinically Relevant Doses

Lead Author and Presenter: Aarif Ahsan, Bristol Myers Squibb, Princeton, NJ, United States

Session: Myeloproliferative Neoplasms - Biology & Translational Research

Publication Only

Publication #PB1702: Efficacy and Safety of Luspatercept Versus Placebo in Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis on JAK2 Inhibitor Therapy and Requiring RBC Transfusions (INDEPENDENCE trial)

Lead Author: Ruben Mesa, Mays Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX, United States

CHRONIC MYELOID LEUKEMIA

Poster Presentation

Presentation #EP677: Effect of Comorbidities on Patient Responses With First-Line Dasatinib Versus Imatinib in Chronic Myeloid Leukemia in Chronic Phase: Exploratory Post Hoc Analysis of DASISION

Lead Author and Presenter: Massimo Breccia, Sapienza University, Rome, Italy

Session: Chronic Myeloid Leukemia - Clinical

© 2021 Bristol-Myers Squibb Company 6/21 NP-WWM-NA-0137

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.